Record water tariff increases finally end, but Europe emerges a new leader

OXFORD, England, Sept 29 (Bernama-GLOBE NEWSWIRE) — Global Water Intelligence (GWI)’s annual Tariff Survey, published on 24th September, found that average global water tariff growth from 2024 to 2025 was 6.2%, putting an end to the record increases seen in the high-inflation post-pandemic years.

Where tariffs are increasing however, the decision is more frequently driven by the needs for long-term investments rather than operational cost recovery, which was driving early post-pandemic increases. 

Unusually, Europe is at the forefront of this year’s tariff increase, with new legislation and investments in climate change resilience driving higher-than-usual increases. Two countries join Europe at the top of the increase table, Turkey and Kazakhstan, with both countries taking seven of the ten spots for top increases in 2025.

In Kazakhstan, the authorities took the plunge with a shift to volumetric tariffs to meet investment needs in ageing infrastructure and resilience. Despite the large increase, tariffs remain low in absolute terms however.

Elsewhere in Asia, where GWI has surveyed 172 cities from 40 countries and territories, growth is sluggish. A few notable increases in India are far from enough to lift the country’s standing in the tariff ranking: South Asia remains by far the cheapest region in the world. 

In Latin America and sub-Saharan Africa, after sustained growth over the past few years, growth is relatively subdued this year, with notable exceptions such as South Africa and Argentina. As for North America, tariff growth is stable, underpinned in many cities by increases in stormwater charges to cope with more extreme weather events.

Become a GWI Member today to access the full dataset, including detailed tariff profiles for 641 cities in 200 countries, in-depth articles, plus all previous tariff survey data dating back to 2011: http://www.globalwaterintel.com.

About Global Water Intelligence

Global Water Intelligence is the leading market intelligence and events company serving the international water industry. Over the last 25 years we have built our business around being a trusted interface between our clients and their markets, providing our customers with high-level intelligence that enables them to make the most informed strategic decisions for their business. We cover municipal markets and every industrial vertical as well as technology, finance and economics.

CONTACT: Emilie Filou
COMPANY: Global Water Intelligence
PHONE: 01865 204208
EMAIL: sales@globalwaterintel.com
WEB: https://www.globalwaterintel.com

SOURCE: Global Water Intelligence

ZENAS BIOPHARMA TO PARTICIPATE IN UPCOMING HEALTHCARE INVESTOR CONFERENCES

WALTHAM, Mass, 8 Nov (Bernama-GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies, today announced the Company’s participation at the following healthcare investor conferences:

  • Guggenheim’s Inaugural Healthcare Innovation Conference on November 12, 2024, in Boston, MA
  • Jefferies London Healthcare Conference on November 19, 2024 presentation at 4:00 p.m. to 4:25 p.m. GDT, in London
  • Citi’s 2024 Global Healthcare Conference on December 3, 2024 presentation at 9:30 a.m. to 10:10 a.m. ET, in Miami, FL
  • Evercore ISI HealthCONx Conference on December 4, 2024 presentation at 1:20 p.m. to 1:40 p.m. ET, in Coral Gables, FL

Live webcasts and archived replays of the Company’s presentations at the Jefferies, Citi and Evercore conferences can be accessed under “Events and Presentations” in the Investors and Media section of the Zenas BioPharma website.

About Zenas BioPharma, Inc.

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s mechanism of action and chronic dosing regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on X at @ZenasBioPharma and LinkedIn.

The Zenas BioPharma word mark and logos are trademarks of Zenas BioPharma, Inc. or its affiliated companies.

Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com

Media Contact:
Argot Partners
Zenas@argotpartners.com

SOURCE : Zenas BioPharma (USA) LLC